COPIKTRA

This brand name is authorized in Austria, Estonia, France, Croatia, Ireland, Italy, Lithuania, Poland, United States

Active ingredients

The drug COPIKTRA contains one active pharmaceutical ingredient (API):

1 Duvelisib UNII 610V23S0JI - DUVELISIB

Duvelisib is a dual inhibitor of phosphatidylinositol 3-kinase p110δ (PI3K-δ) and PI3K-γ. PI3K-δ inhibition directly reduces proliferation and survival of malignant B-cell lines and primary CLL tumour cells, while PI3K-γ inhibition reduces the activity of CD4+ T cells and macrophages in the tumor microenvironment to support the malignant B cells. Read about Duvelisib

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
COPIKTRA Capsule	FDA, National Drug Code (US)	MPI, US: SPL/PLR
COPIKTRA Hard capsule	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01EM04		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EM Phosphatidylinositol-3-kinase (Pi3K) inhibitors
Discover more medicines within L01EM04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1849305, 1849316
Country: FR	Base de données publique des médicaments	Identifier(s): 62881517, 69954156
Country: IT	Agenzia del Farmaco	Identifier(s): 049523018, 049523020
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1092668, 1092669
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100455394, 100455407
Country: US	FDA, National Drug Code	Identifier(s): 71779-115, 71779-125